These projects were made possible from Cure Alzheimer's Fund support.
Project Description | Researchers | Funding |
---|---|---|
Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein During Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure |
2023, 2025 $290,605 |
These published papers resulted from Cure Alzheimer’s Fund support.
Barba, L., Bellomo, G., Alcolea, D., Wojdala, A. L., Gaetani, L., Fortea, J., Abu-Rumeileh, S., Lleó, A., Parnetti, L., Belbin, O., Otto, M., & Oeckl, P. Serum level changes of the synaptic marker beta-synuclein in Alzheimer’s disease continuum and other dementias, Journal of Neurology, Neurosurgery, and Psychiatry, June 26, 2025, Read More
Doecke, J. D., Bellomo, G., Vermunt, L., Alcolea, D., Halbgebauer, S., ... Otto, M., Hansson, O., … Teunissen, C. Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer’s disease and non-AD dementias: An international multi-center study, Alzheimer's & Dementia, June 23, 2025, Read More
Oeckl, P., Mayer, B., Bateman, R. J., Day, G. S., Fox, N. C., Huey, E. D., Ibanez, L., Ikeuchi, T., Jucker, M., Lee, J. H., Levin, J., Llibre-Guerra, J. J., Lopera, F., McDade, E., Morris, J. C., Niimi, Y., Roh, J. H., Sánchez-Valle, R., Schofield, P. R., Otto, M., & Dominantly Inherited Alzheimer Network Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer’s disease, Alzheimer's & Dementia, April 10, 2025, Read More